Equities Analysts Set Expectations for HURA FY2027 Earnings

TuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities research analysts at Zacks Small Cap issued their FY2027 earnings per share estimates for shares of TuHURA Biosciences in a research report issued to clients and investors on Monday, May 19th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.64) per share for the year.

Separately, HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of TuHURA Biosciences in a research report on Friday, May 16th.

TuHURA Biosciences Trading Down 1.3%

Shares of HURA opened at $3.72 on Wednesday. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.93. The business's fifty day moving average is $3.75 and its 200-day moving average is $4.07.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Accent Capital Management LLC purchased a new position in shares of TuHURA Biosciences during the 4th quarter valued at $29,000. TT Capital Management LLC bought a new position in shares of TuHURA Biosciences during the fourth quarter valued at about $41,000. Jefferies Financial Group Inc. bought a new position in shares of TuHURA Biosciences during the fourth quarter valued at about $54,000. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences during the fourth quarter valued at about $59,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of TuHURA Biosciences during the fourth quarter valued at about $61,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.